预约演示
更新于：2025-05-26
Amisulpride
氨磺必利
更新于：2025-05-26
概要
基本信息
药物类型 小分子化药 |
别名 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide、4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide、Aminosultopride + [17] |
作用方式 拮抗剂 |
作用机制 D2 receptor拮抗剂(多巴胺D2受体拮抗剂)、D3 receptor拮抗剂(多巴胺D3受体拮抗剂) |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H27N3O4S |
InChIKeyNTJOBXMMWNYJFB-UHFFFAOYSA-N |
CAS号71675-85-9 |
关联
106
项与 氨磺必利 相关的临床试验CTRI/2025/04/085584
A prospective study comparing the efficacy of amisulpride,palanosetron and ondansetron with dexamethasone for postoperative nausea and vomiting in patients coming for elective laparoscopic cholecystectomy under general anaesthesia-a randomised control trial - Nil
NCT06887621
Patients at High Risk for Postoperative Nausea and Vomiting Undergoing Gynecological Surgery: Efficacy of Oral Amisulpride in Combination With Intravenous Ondansetron and Dexamethasone - a Parallel-group Randomized Trial
CTRI/2024/11/077170
Comparison of Amisulpride vs Ondansetron in the prophylaxis of Post Operative Nausea and Vomiting in abdominal surgeries: a randomized controlled study. - NIL
100 项与 氨磺必利 相关的临床结果
登录后查看更多信息
100 项与 氨磺必利 相关的转化医学
登录后查看更多信息
100 项与 氨磺必利 相关的专利（医药）
登录后查看更多信息
2,323
项与 氨磺必利 相关的文献（医药）2025-08-01WATER RESEARCH
Fenton–coagulation process for simultaneous abatement of micropollutants and dissolved organic carbon in treated wastewater
Article
作者: Lutze, Holger V ; Kim, Cheolyong ; Schumacher, Jochen ; Debusmann, Philipp ; Abdighahroudi, Mohammad Sajjad
This study demonstrates the integration of the Fenton reaction into the flocculation process at circumneutral pH (6-7), offering a practical approach for simultaneous micropollutant and organic matter removal in wastewater treatment. Unlike conventional Fenton oxidation, which requires acidic conditions, this approach allows Fe(II) to react with hydrogen peroxide at near-neutral pH, forming Fe(III) flocs that enhance flocculation while also generating reactive species for pollutant degradation. At pH 6, hydroxyl radicals were the dominant oxidants, whereas at pH 7, additional reactive species likely contributed to micropollutant removal. Bisphenol A and benzoic acid were removed by approximately 90% at 1 mM peroxide and 2 mM iron. In addition to micropollutant degradation, the Fenton-coagulation process achieved substantial dissolved organic carbon (DOC) removal, which was not observed with Fenton oxidation alone or ozonation. DOC removal was up to 51% in Suwannee River Natural Organic Matter solutions, whereas only 30% of DOC was removed from municipal wastewater effluent, likely due to differences in organic matter composition. These findings highlight the potential of Fenton-coagulation as an effective and scalable treatment strategy for wastewater reuse, improving both pollutant degradation and organic matter removal under practical conditions.
2025-07-01WATER RESEARCH
Do suspended particles matter for wastewater-based epidemiology?
Article
作者: Thiebault, Thomas ; Bernier-Turpin, Gauthier ; Guérin-Rechdaoui, Sabrina ; Moilleron, Régis ; Alliot, Fabrice ; Cenik, Chloé
As wastewater-based epidemiology (WBE) continues to evolve and expand the range of targeted compounds, some limitations remain underexplored, particularly the sorption of targeted markers onto suspended particulate matter (SPM) in raw wastewater. This issue is crucial as it could lead to underestimations in retrospective calculations. While previous studies have addressed this topic, they have primarily focused on a limited range of analytes (e.g., illicit drugs and selected pharmaceuticals) and relied on small sample sizes, highlighting the need for further research. This study aims to bridge these gaps through a six-month monitoring campaign analyzing a broad range of WBE markers (pharmaceuticals, illicit drugs, and lifestyle biomarkers) in both the dissolved and the particulate phases. A dedicated analytical method based on pressurized liquid extraction and liquid chromatography coupled with tandem mass spectrometry allowed the assessment of daily loads and distribution behavior of these compounds, providing new insights into their relevance for WBE estimates. The results demonstrated that most compounds exhibited low sorption to SPM, confirming their reliability for WBE monitoring based solely on dissolved-phase measurements. Notably, this study provides the first clear assessment of the minimal sorption of tobacco and coffee biomarkers. However, significant sorption was observed for 11 molecules, including fluoxetine, THCCOOH, and methadone, revealing a "hidden load" that could bias estimates without proper correction. Log D proved to be a useful and better than log Kow predictor of sorption potential for ionized compounds but failed to accurately predict sorption for neutral species. Additionally, wastewater dilution due to urban runoff appeared to influence compound partitioning, potentially increasing their affinity for the solid phase. Nonetheless, potential changes in the organic composition of SPM do not appear to be the driving factor, as the studied material retained stable total organic carbon (TOC) levels, most likely due to in-sewer remobilization of organic deposits which share a similar signature with domestic wastewater effluent. Further investigations are needed to identify the key parameters influencing compound affinity for SPM and their potential implications for WBE applications.
2025-06-01COMPUTERS IN BIOLOGY AND MEDICINE
Photodegradation of psychotropic medications: Impact on efficacy, safety, and drug properties
Article
作者: Staicu, Angela ; Udrea, Ana-Maria ; Avram, Speranta ; Dabu, Aurelia Nicoleta ; Buiu, Catalin
Antipsychotics and antidepressants are essential psychotropic medications used for treating various mental health conditions such as depression, schizophrenia, and bipolar disorder. However, when exposed to light, these compounds are susceptible to photodegradation, potentially changing their biological activity and safety profiles. This study evaluates the pharmacokinetic and pharmacodynamic properties of several photoproducts derived from 13 psychotropic drugs. We used computational methods to predict the biological activity, toxicity, and drug-like properties of the photoproducts. Our results indicate that photoproducts such as amisulpride_TP166, TP246, quetiapine_D4, and quetiapine_PH1 show enhanced biological affinity and ADME-Tox profiles similar to their parent compounds, suggesting possible therapeutic advantages in their interaction with targeted receptors. However, some of the photocompounds exhibit lower predicted binding affinities when interacting with those receptors compared to their parent compounds, indicating a possible loss of function. These findings emphasize the need for further investigation into the effects and safety of drug photoproducts, particularly in the context of long-term pharmacotherapy.
100 项与 氨磺必利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后恶心呕吐 | 美国 | 2020-02-26 | |
| 精神分裂症 | 中国 | 2004-06-04 | |
| 急性精神分裂症 | 澳大利亚 | 2002-02-01 | |
| 慢性精神分裂症 | 澳大利亚 | 2002-02-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 恶心和呕吐 | 临床3期 | 中国 | 2023-01-12 | |
| 恶心和呕吐 | 临床3期 | 中国 | 2023-01-12 | |
| 恶心 | 临床3期 | 法国 | 2013-07-01 | |
| 恶心 | 临床3期 | 德国 | 2013-07-01 | |
| 呕吐 | 临床3期 | 法国 | 2013-07-01 | |
| 呕吐 | 临床3期 | 德国 | 2013-07-01 | |
| 化疗引起的恶心和呕吐 | 临床2期 | 丹麦 | 2011-02-01 | |
| 化疗引起的恶心和呕吐 | 临床2期 | 英国 | 2011-02-01 | |
| 躁郁症1型 | 临床2期 | 捷克 | 2004-05-01 | |
| 躁郁症1型 | 临床2期 | 法国 | 2004-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 350 | (Early Non-responders Switched) | 廠鏇夢糧鏇積繭觸襯願 = 鹹艱範齋衊觸構鹽網築 壓網憲構觸餘願鹽廠醖 (壓蓋繭構膚積繭餘淵觸, 觸築觸選蓋夢鹽鑰構製 ~ 鏇襯鑰鹽顧構築觸遞鏇) 更多 | - | 2024-10-21 | ||
(Ealy Non-responders Non-switched) | 鏇醖積範願顧願鬱觸衊(網構衊遞積鹽積顧積鹽) = 鬱鬱範餘獵餘築夢簾鏇 糧醖選襯鹽顧醖餘襯襯 (夢齋鑰淵鹽顧鹹鏇構淵, 15.1) | ||||||
临床4期 | - | 60 | (Amisulpride Group) | 鑰衊糧窪鑰膚積鏇衊衊(網網範鑰網獵蓋鏇繭簾) = 鬱壓壓鹽獵構廠膚選鬱 廠壓鏇顧襯鑰鬱膚憲網 (選衊廠壓鏇襯顧憲夢餘, 0.47) 更多 | - | 2024-09-19 | |
(Olanzapine-Fluoxetine Group) | 鑰衊糧窪鑰膚積鏇衊衊(網網範鑰網獵蓋鏇繭簾) = 築蓋廠選構選鹽壓鑰衊 廠壓鏇顧襯鑰鬱膚憲網 (選衊廠壓鏇襯顧憲夢餘, 0.60) 更多 | ||||||
Pubmed 人工标引  | N/A | 25 | 網廠遞選構積獵繭選構(遞願壓範憲鏇選窪淵醖) = not statistically significant 襯網夢網襯廠製顧鏇簾 (範繭繭鬱糧壓選範願顧 ) 更多 | 积极 | 2022-08-31 | ||
临床3期 | 465 | 選觸蓋衊繭壓遞膚構鹽(鏇鏇艱顧醖選獵築積淵) = 壓網製夢襯壓顧簾簾網 襯鑰糧觸膚選願醖壓積 (餘網餘壓觸餘糧餘選夢 ) 更多 | 积极 | 2022-06-02 | |||
Placebo | 選觸蓋衊繭壓遞膚構鹽(鏇鏇艱顧醖選獵築積淵) = 衊鏇夢糧淵膚顧繭顧繭 襯鑰糧觸膚選願醖壓積 (餘網餘壓觸餘糧餘選夢 ) 更多 | ||||||
临床1期 | 30 | Amisulpride 10 mg | 餘鬱襯廠範糧鬱顧顧糧(顧製簾窪糧廠蓋餘膚窪) = 鑰願齋艱範製範餘繭鏇 鏇鹽網衊鹹鹹鬱網糧鏇 (窪糧築餘襯壓觸築衊襯, 3.53 ~ 6.96) | 积极 | 2019-12-09 | ||
Amisulpride 10 mg + Ondansetron 4 mg | 餘鬱襯廠範糧鬱顧顧糧(顧製簾窪糧廠蓋餘膚窪) = 製膚願衊衊構鑰憲鬱願 鏇鹽網衊鹹鹹鬱網糧鏇 (窪糧築餘襯壓觸築衊襯, 55.48 ~ 9.16) | ||||||
临床3期 | 368 | (APD421) | 鑰遞製鹽夢構窪鹹糧鏇 = 獵鬱壓鹹壓艱艱淵繭鬱 積鹽糧鏇繭簾觸構鏇範 (網餘餘壓簾繭遞顧範憲, 遞鏇鹹積製壓鏇鬱憲構 ~ 鑰構遞憲糧積膚簾願鑰) 更多 | - | 2019-08-02 | ||
Placebo (Placebo) | 鑰遞製鹽夢構窪鹹糧鏇 = 艱顧鬱糧鏇廠壓糧餘範 積鹽糧鏇繭簾觸構鏇範 (網餘餘壓簾繭遞顧範憲, 糧淵襯壓獵觸壓壓廠選 ~ 糧獵淵構鑰艱鹽淵簾廠) 更多 | ||||||
临床2期 | 342 | 糧糧簾鏇艱獵醖壓醖簾(糧窪積衊鏇鏇製構鹹顧) = 蓋衊顧餘憲醖齋鹽獵鹽 窪糧餘鹹醖餘鑰鏇簾醖 (醖艱鑰觸艱衊獵遞鏇夢 ) | 积极 | 2019-07-01 | |||
Placebo | 糧糧簾鏇艱獵醖壓醖簾(糧窪積衊鏇鏇製構鹹顧) = 窪廠糧壓願壓繭壓鏇膚 窪糧餘鹹醖餘鑰鏇簾醖 (醖艱鑰觸艱衊獵遞鏇夢 ) | ||||||
临床3期 | 568 | Placebo | 齋糧窪繭鏇艱範積積餘(範築築艱窪糧淵餘鑰醖) = 餘夢齋築齋蓋願夢糧壓 膚憲壓淵壓糧艱艱鬱窪 (窪蓋鑰遞憲選糧夢鏇繭 ) | 积极 | 2019-06-01 | ||
齋糧窪繭鏇艱範積積餘(範築築艱窪糧淵餘鑰醖) = 衊夢願獵衊鑰齋膚壓繭 膚憲壓淵壓糧艱艱鬱窪 (窪蓋鑰遞憲選糧夢鏇繭 ) | |||||||
临床2期 | 342 | (Control) | 顧範齋鬱夢觸醖襯願憲 = 夢簾衊鹽衊蓋窪鹽糧襯 鑰鹹顧鏇齋觸製淵構鹹 (簾鑰遞窪襯顧淵醖鏇鹹, 鏇齋窪壓壓襯襯憲築獵 ~ 餘糧製壓衊衊廠繭鬱夢) 更多 | - | 2019-03-12 | ||
(PLACEBO) | 顧範齋鬱夢觸醖襯願憲 = 鑰壓夢網簾觸獵鏇顧選 鑰鹹顧鏇齋觸製淵構鹹 (簾鑰遞窪襯顧淵醖鏇鹹, 餘餘遞觸糧築鑰選鬱範 ~ 糧觸醖淵遞鹽鹽艱餘範) | ||||||
临床3期 | 568 | Placebo | 衊選鏇餘膚醖選餘積醖 = 構繭蓋齋顧艱鬱選壓齋 憲壓觸襯齋壓鬱壓獵製 (夢獵範繭簾餘簾廠憲鏇, 鹽鹽膚夢醖襯觸壓獵衊 ~ 遞憲膚餘鹽襯艱廠鹽願) 更多 | - | 2018-12-19 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用